DGAP-News: CytoTools AG / Key word(s): Quarter Results/Market launch 
CytoTools Q1 Trading Update: Treatment numbers in India slightly above previous quarter despite significant pandemic 
impact 
2021-06-21 / 09:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
CytoTools Q1 Trading Update: Treatment numbers in India slightly above previous quarter despite significant pandemic 
impact 
- Over 10,000 use cases in Q1 despite tough lockdown in India 
- Expansion into Africa following provisional approval of Woxheal in Kenya 
Darmstadt, 21 June 2021 - CytoTools AG (ISIN DE000A0KFRJ1), a biotechnology holding company specializing in 
pharmaceutical and medical products, has received a trading update on the first quarter of 2021 from its licensing 
partner Centaur Pharmaceuticals on the drug Woxheal(R) for the treatment of the Diabetic Foot Syndrome. According to 
the update, despite significant pandemic-related sales hinderances, sales of Woxheal(R) in India have increased 
slightly to over 10,000 use cases compared to the fourth quarter of 2020. 
"Of course, it still has to be said that these figures are still significantly below our expectations and the 
expectations of our license partner," underlines Dr. Mark-André Freyberg, CEO of CytoTools. "At the same time, however, 
the figures show that the treating physicians are convinced of the drug, continue to prescribe it and that the active 
ingredient is achieving very good treatment results as expected." Based on current significantly declining COVID-19 
incidence numbers in India, the company is confident that the number of treatments can increase noticeably in the 
second half of 2021 and that the roll-out of the product will be accelerated as originally planned. 
In addition, Centaur Pharmaceuticals has informed the Company that it has now received tentative approval for Woxheal 
(R) in Kenya, Africa. Provisional approval of a drug can be granted in Kenya without additional studies based on the 
approval of the India Central Drugs Standard Control Organization (CDSCO). In parallel, Centaur is seeking approval for 
the drug in other African countries where a basically similar approval process is possible. "We would also like to 
emphasize for this market that we have to assume a very subdued marketing start against the background of COVID-19 and 
our experience from India," emphasizes Dr. Dirk Kaiser, Board Member for Research & Development at CytoTools. 
"Nevertheless, we regard this step as very positive, as it underpins the high value that is attached to the active 
ingredient DPOCL in other countries as well. It underlines the high relevance of the approval in India internationally 
and we assess the chances of a successful outcome of the clinical phase III in Europe as still very high." CytoTools 
initiated Phase III clinical trials of its DPOCL compound in Europe in the first quarter of 2021. Despite delays due to 
the progress of COVID-19 in Europe, the Management Board assesses the current progress of the study as still on track. 
Therefore, the company still expects to be able to report interim results of the study at the end of 2021 and then to 
successfully complete Phase III by the end of 2022. 
Against the background of the marketing delays in India triggered by COVID-19, the Management Board of CytoTools AG, in 
consultation with the Supervisory Board, has decided to reduce the size of the Board of Directors again from three to 
two members and to divide the responsibilities of the Chief Financial Officer Marc Herwick between the two other 
members of the Board of Directors. "We created the position of Chief Financial Officer largely against the background 
of a rapid roll-out of Woxheal in India. However, in the current environment, this clearly seems premature," explains 
CEO Dr. Mark-André Freyberg. "Although we continue to be well financed, we keep close control on the budget and want to 
use our liquidity in a targeted manner for the further development of our operating business. Therefore, we have 
reached a mutual agreement with Mr. Herwick to terminate our cooperation. We thank him for his efforts for the company 
and wish him all the best personally and professionally." 
Additional information about CytoTools AG, its affiliated subsidiaries and the holding company's drug pipeline is 
available on the company's website at www.cytotools.de. 
Contact: 
CytoTools AG 
Ingo Middelmenne 
Investor Relations 
Mobile: +49-174-9091190 
Email: middelmenne@cytotools.de 
About CytoTools: 
CytoTools AG is a German biotechnology holding company that translates results from basic cell biology research on cell 
growth and programmed cell death into novel therapies for causal disease treatment and cure. CytoTools' versatile 
product pipeline includes proprietary chemical compounds and biopharmaceuticals that have the potential to provide new 
treatment options in dermatology, cardiology, urology and oncology. CytoTools is structured as a technology holding and 
investment company and holds interests in its subsidiaries DermaTools Biotech GmbH (65%) and CytoPharma GmbH (50%). 
Disclaimer 
This release contains certain forward-looking statements. These reflect the views of CytoTools as of the date of this 
release. Actual results achieved by CytoTools may differ materially from the findings in the forward-looking 
statements. CytoTools is under no obligation to update any forward-looking statements. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-21 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      CytoTools AG 
              Klappacher Str. 126 
              64285 Darmstadt 
              Germany 
Phone:        +49 (0)6151-951 58 12 
Fax:          +49 (0)6151-951 58 13 
E-mail:       kontakt@cytotools.de 
Internet:     www.cytotools.de 
ISIN:         DE000A0KFRJ1 
WKN:          A0KFRJ 
Listed:       Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate 
              Exchange 
EQS News ID:  1210083 
 
End of News   DGAP News Service 
=------------ 

1210083 2021-06-21


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1210083&application_name=news

(END) Dow Jones Newswires

June 21, 2021 03:31 ET (07:31 GMT)